Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimum effective dose of intravenous amisulpride (APD421) for prevention of cisplatin-induced nausea and vomiting
2010-022170-14Phase 2Completed
- Sponsor
- Acacia Pharma Group Plc
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amisulpride in chemotherapy-induced nausea and vomiting (CINV), sponsored by Acacia Pharma Group Plc. Primary endpoint: Complete response in acute phase. Started Nov 2010; status: completed.
02
Drugs
amisulpride
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2010-022170-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022170-14.